KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Liabilities: 2009-2024

Historic Total Liabilities for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $160.7 million.

  • Rigel Pharmaceuticals' Total Liabilities fell 18.91% to $124.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.9 million, marking a year-over-year decrease of 18.91%. This contributed to the annual value of $160.7 million for FY2024, which is 10.16% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Total Liabilities of $160.7 million as of FY2024, which was up 10.16% from $145.9 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Total Liabilities high stood at $160.7 million for FY2024, and its period low was $76.4 million during FY2020.
  • In the last 3 years, Rigel Pharmaceuticals' Total Liabilities had a median value of $147.9 million in 2022 and averaged $151.5 million.
  • In the last 5 years, Rigel Pharmaceuticals' Total Liabilities declined by 18.56% in 2020 and then skyrocketed by 79.37% in 2021.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Total Liabilities stood at $76.4 million in 2020, then surged by 79.37% to $137.0 million in 2021, then rose by 7.99% to $147.9 million in 2022, then fell by 1.37% to $145.9 million in 2023, then rose by 10.16% to $160.7 million in 2024.